Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.
The Fund has now invested a total of USD 30 million in six companies
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.
Recipharm AB will publish its interim report for January - June 2019 on 25th July at 07:45 am CET.
Revenue and EBITDA for full year 2019 expected to be ahead of market expectations
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, announces the results of its rights issue for a limited amount of € 521 K.
Turku, Finland, July 19th 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, announces that Sunstone Life Science Ventures has made a €5 million investment in Forendo.
MyoKardia, Inc. announced updates related to its hypertrophic cardiomyopathy treatment portfolio, including lead therapeutic candidate, mavacamten.
Assertio Therapeutics, Inc. announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets.